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Introduction
In addition to the well-known phenomenon of transcriptional 
regulation by DNA methylation, epigenetic regulation is also 
largely mediated by acetylation and methylation of histone lysine 
residues within their N-terminal “tails” that emanate from the 
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core nucleosome histone octamer. Five extensively modified resi-
dues include lysines 4, 9, 14, 27 and 36 of histone H3 (H3K4, 
H3K9, H3K14, H3K27 and H3K36 respectively).1 Of these, 
H3K4, H3K9, H3K27 and H3K36 are mono-, di- or trimethyl-
ated by distinct histone methyltransferases and histone demeth-
ylases, while H3K9 and H3K14 are also frequently acetylated by 
“Epigenetic plasticity” refers to the capability of mammalian cells to alter their differentiation status via chromatin 
remodeling-associated alterations in gene expression. While epigenetic plasticity has been best associated with lineage 
commitment of embryonic stem cells, recent studies have demonstrated chromatin remodeling even in terminally 
differentiated normal cells and advanced-stage melanoma and breast cancer cells, in context-dependent responses to 
alterations in their microenvironment. In the current study, we extend this attribute of epigenetic plasticity to aggressive 
ovarian cancer cells, by using an integrative approach to associate cellular phenotypes with chromatin modifications (“chIp-
chip”) and mRNa and microRNa expression. While we identified numerous gene promoters possessing the well-known 
“bivalent mark” of h3K27me3/h3K4me2, we also report 14 distinct, lesser known bi-, tri- and tetravalent combinations 
of activating and repressive chromatin modifications, in platinum-resistant cp70 ovarian cancer cells. The vast majority 
(>90%) of all the histone marks studied localized to regions within 2,000 bp of transcription start sites, supporting a 
role in gene regulation. Upon a simple alteration in the microenvironment, transition from two- to three-dimensional 
culture, an increase (17–38%) in repressive-only marked promoters was observed, concomitant with a decrease (31–21%) 
in multivalent (i.e., juxtaposed permissive and repressive histone marked) promoters. Like embryonic/tissue stem and 
other (non-ovarian) carcinoma cells, ovarian cancer cell epigenetic plasticity reflects an inherent transcriptional flexibility 
for context-responsive alterations in phenotype. It is possible that this plasticity could be therapeutically exploited for 
the management of this lethal gynecologic malignancy.
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was also strikingly demonstrated by the differentiation of highly 
aggressive melanoma, breast and prostate cancer cells,22 follow-
ing exposure to embryonic stem cell (ESC)-derived extracellular 
matrices.23 Similarly, malignant reversion of breast cancer and 
acute myelogenous leukemia cells followed antibody-mediated 
disruption of integrin binding, while abnormal stromal fibro-
blasts and loss of laminin-1-associated polarity, are now strongly 
associated with a number of carcinomas.24,25 Moreover, in sup-
port of a role for epigenetic plasticity during the process of onco-
genesis, numerous ESC-bivalently marked genes (mostly tumor 
suppressors) were also DNA-methylated in adult colon cancer 
tumors,6,26 while numerous bivalent promoters were also iden-
tified in both normal and malignant prostate tissues (although 
the specific bivalently marked genes differed between malignant 
and normal prostate cells).27 Together, these studies demonstrate 
that even genetically damaged cancer (or senescent, normally 
differentiated) cells can drastically alter their cellular phenotype, 
via chromatin remodeling, in response to perturbations in the 
microenvironment.
In this report, we examine whether aggressive, chemoresis-
tant CP70 ovarian cancer cells also possess epigenetic plasticity 
(similar to other carcinomas), by assessing chromatin alterations 
associated with a simple change in their microenvironment, the 
transition from anchorage-dependent (“2D,” as cell monolayers) 
to anchorage-independent culture conditions (“3D,” as spherical 
aggregates). Similar tumor-derived spheroids are commonly seen 
in the ascites of ovarian cancer patients,28 and a recent study of 
an ovarian cancer cell line part demonstrated widespread gene 
expression changes in spheroids, in cell culture, following chemo-
therapy treatment.29 Consequently, we hypothesized that epigen-
etic plasticity, inherent to other (non-ovarian) carcinoma cells, 
might also facilitate adaptation to three-dimensional culturing. 
Using ChIP-chip analyses, we identified “epigenetic signatures” 
of CP70 cells, ovarian cancer stem-like cells and patient-derived 
tumors, while also characterizing a number of previously little-
known multivalent combinations of active (H3Ac, H3K4me2) 
and repressive (H3K9me3, H3K27me3) histone marks. Similar 
to the well known bivalent domains of H3K27me3/H3K4me2/3 
in stem cells, these multivalently marked promoters also con-
ferred epigenetic plasticity to CP70 cells, in correlation with 
distinct changes in gene expression. Consequently, as in other 
carcinomas, a better understanding of chromatin plasticity in 
serous epithelial ovarian cancer may facilitate epigenetic strate-
gies for ameliorating (or even reversing) the tumor-progressive 
and metastatic phenotypes of this disease.
Results
transcriptionally repressive and permissive histone marks pre-
dominantly flank gene promoters and first exons in ovarian 
cancer cells. To assess the presence of multivalent (juxtaposed 
permissive and repressive, suggestive of epigenetic plasticity) 
histone modifications in ovarian cancer cells, two transcription-
ally permissive chromatin marks, acetylated H3 (H3Ac) and 
H3K4me2 and two repressive marks, H3K9me3 and H3K27me3, 
were examined in CP70 ovarian cancer cells cultured under 
histone acetyltransferases.1 While DNA methylation is mostly 
repressive of gene transcription,2 distinct histone modifications 
can facilitate a variety of biological outcomes, as set forth by the 
“histone code” hypothesis, which posits that specific histone 
alterations (i.e., the “written” code) are “read” by their cognate 
chromatin-interacting proteins to bring about unique (down-
stream) biological events, including the activation or repression 
of gene transcription (i.e., the “interpretation” of the code).3,4
Repressive histone marks frequently coordinate with (the 
more permanent mark of) DNA methylation5 in heterochro-
matin, while embryonic and tissue stem cells possess numer-
ous gene promoters concurrently having two opposing histone 
marks, the transcriptionally activating di-/tri-methylated H3K4 
(H3K4me2/3) and the transcriptionally repressive trimethylated 
H3 lysine 27 (H3K27me3), marks.6,7 In stem cells, such promoter 
“bivalency” allows for transcriptional flexibility (“epigenetic 
plasticity”) that is subsequently restricted during differentiation-
associated lineage commitment.8,9 In cancer cells, however, biva-
lency has been hypothesized to “mark” specific genes for (the 
more permanently repressive) DNA methylation,10-12 H3K27 
trimethylation can also mediate gene silencing (in the absence of 
DNA methylation), by the commonly overexpressed oncoprotein 
EZH2.13,14
Although epigenetic plasticity is predominant in embryonic 
and tissue stem cells,6,7 recent studies have also shown that even 
in terminally differentiated, senescent cells, epigenetic modifica-
tions are potentially reversible to allow “reprogramming” to an 
altered differentiation level. One of the most dramatic examples 
of epigenetic reprogramming is found in studies of “induced 
pluripotency,” in which terminally differentiated somatic cells, 
including mouse fibroblasts, keratinocytes, intestinal epithelial 
and muscles cells were (by ectopic introduction of various tran-
scription factors or drugs) restored to an embryonic-like pluripo-
tent phenotype capable of producing chimeric mice and in rare 
cases, germline integration.15,16 Another example of epigenetic 
plasticity is “transdifferentiation” of various differentiated cells 
from one lineage to another.17
While epigenetic plasticity is essential for normal differen-
tiation of pluripotent stem cells, the recent “cancer stem cell” 
hypothesis of carcinogenesis likewise suggests a tumor cell hier-
archy similar to that of normal organs (and indeed, tumors have 
been suggested to represent “abnormal organs”), with tumor 
growth, “differentiation,” and propagation instigated by a dis-
tinct subset of malignant progenitors (“cancer stem cells”).18,19 In 
support of this hypothesis, highly aggressive (possibly stem-like) 
cancer cells demonstrate considerable epigenetic flexibility (likely 
allowing adaptation to diverse microenvironments and immune 
evasion), including an intricate type of transdifferentiation, the 
epithelial-to-mesenchymal transition (EMT), a normal (micro-
environment-regulated) cell detachment/dispersal and mobility 
process essential for embryogenesis.20 Analogously, however, in 
cancer cells, EMT facilitates metastatic tumor cell detachment, 
migration, basement membrane invasion and establishment of 
secondary lesions,20 and a recent breast cancer study revealed 
extensive chromatin remodeling associated with EMT induced 
by TGFb.21 Epigenetic plasticity of advanced stage cancer cells 
718 Epigenetics Volume 5 Issue 8
domains to ovarian cancer cells, including the well-characterized 
H3K4me2-H3K27me3 mark, in addition to other little-reported 
combinations of active (H3Ac, H3K4me2) and repressive 
(H3K9me3, H3K27me3) chromatin modifications present in 
distinct bivalent, trivalent and tetravalent associations. Those 
previously uncharacterized promoter combinations include 
the bivalent combinations H3K4me2/H3K9me3, H3K4me2/
H3K27me3, H3Ac/H3K27me3 or H3Ac/H3K9me3, the triva-
lent combinations H3K42me2/H3K9me3/H3K27me3, H3Ac/
H3K4me2/-H3K27me3, H3Ac/H3K9me3/H3K27me3, H3Ac/
anchorage-dependent (2D) or -inde-
pendent (3D) conditions. By chroma-
tin immunoprecipitaton (ChIP), using 
antibodies against these four specific 
histone modifications, followed by 
hybridization to 244K tiled CpG island 
microarrays (Agilent G4492A Human 
CpG island array; “ChIP-on-chip”), in 
conjunction with our previously devel-
oped “peaksPicking” program for iden-
tifying the most statistically confident 
hybridization fluorescent signals,30 we 
identified a total of 5,053 epigenetically 
marked genes under the two condi-
tions. All four H3 marks were detected 
equally in the ChIP-chip experiments 
and the regions containing these marks 
(i.e., the hybridized microarray fluores-
cence signal peaks) were quite similar 
in size (median value of ~300 bp), with 
a few long tails stretching to 5,000 bp 
(fig. 1a). Each mark was easily iden-
tified even within the more stringent 
top 5% and top 2% of the peaksPick-
ing results, although multivalent marks 
were somewhat less frequently observed 
in the top 5% than in the top 10% of 
hybridized loci (suppl. fig. s1).
Chromosomal alignment revealed 
these histone marks to preferentially 
locate in gene promoters, rather than 
intragenic regions (fig. 1B). More pre-
cisely, comprehensive location analy-
sis using the human genome (HG17) 
browser (genome.ucsc.edu) further 
revealed these histone marks to be 
largely proximal (-2,000 bp to +2,000 
bp, fig. 1c) to transcription start sites 
(TSSs). Subsequently, utilizing our 
peaksPicking program, we further 
studied the top 10% of peaks from 
CP70 cells grown under 2D (2734 
total ChIP-hybridized genes) or 3D 
(2,424 total genes) conditions (fig. 2a). 
Both peaksPicking and Integrated 
Genome Browser (www.igb.org) analy-
ses revealed multiple (often opposing) histone marks to occupy any 
given promoter region.
In embryonic and various tissue stem cells, numerous gene 
promoter regions coordinately possess the transcriptionally per-
missive histone marks H3K4me2/3 and the transcriptionally 
repressive H3K27me3 mark, to create a “bivalent” epigenetic sig-
nature and remain “poised” for further, differentiation-associated 
activation or repression.6 ChIP-chip analyses revealed these four 
H3 modifications to occur in 15 distinct combinations, allowing 
us to now extend this phenomenon of “multivalent” epigenomic 
Figure 1. Genome-wide identification of genes associated with specific histone modifications 
in drug-resistant ovarian cancer cells. (a) Relative peak intensity for each mark. Target genes 
were identified using a peakspicking program developed by Jin et al. (Genome Research 2006). 
percentages of genes were calculated based on the total number of genes identified in the top 
10% of genes from the agilent array. a plot of each binding site based on the size of occupancy 
into a particular bin with an increment of 100 bp for each bin. (B) histone h3 marks in Intragenic 
vs. promoter cpG islands (cpGIs). Number of individual peaks for each of the four h3 modifications 
examined (based on cpGIs featured on the array). The top 10% of the total hybridized microarray 
features (using peakspicking software, see text for details) were used for the analysis. (c) Genes 
with h3 marks in proximity to transcriptional start sites (Tsss). histone mark occupancies were 
predominately located in regions corresponding to -2 kb to 2 kb relative to the Tss.
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permissive mark, however, remained the most 
abundant univalent mark in 2D cells, although 
its combination with other histone marks was 
fairly infrequent, with its greatest colocaliza-
tion occurring in the tetravalent mark H3Ac-
H3K4me2/-H3K9me3/H3K 27ME3me3 
(fig. 2B). Also in 2D cells, the well-known 
bivalent H3K4me2/H3K27me3 combination 
(a stem cell histone mark associated with “tran-
scriptional readiness”)26,31 was more prevalent 
in 3D than in 2D cells (6.8 vs. 1%, respec-
tively), as was the previously little-studied triva-
lent mark H3K4me2/H3K9me3/H3K27me3 
(3D cells, 9.7% vs. 2D cells, 0.3%, fig. 2B). 
We also observed two other previously unchar-
acterized combinations, including triva-
lent H3Ac/H3K4me2/H3K9me3 domains 
(present only in 3D cells) and a tetravalent 
combination, H3Ac/H3K4me3/H3K9me3/-
H3K27me3 (present only in 2D cells, fig. 2B); 
these newly characterized mutlivalent marks 
suggest an alternative means to transcrip-
tional flexibility. Together, these results suggest 
that this commonplace change in CP70 cell 
microenvironment (i.e., transition from 2D 
monolayers to 3D spheres) induces extensive 
chromatin remodeling that facilitates pheno-
typic adaptation.
several multivalent epigenetic marks in 
2d cells become monovalent upon 3d cultur-
ing. We next globally assessed the similarity 
(or divergence) of the total changes in the four 
abovementioned histone H3 marks upon 2D 
to 3D transition. Of all the array-hybridized 
genes possessing any of the four H3 marks in 
2D (2,734 total genes) and 3D (2,319 genes, 
fig. 2a) cells (using the top 10% of ChIP-
hybridized genes from our peaksPicking pro-
gram), we found only 1,149 (42%) genes to 
overlap (thus possessing at least one of the four marks in both 
cellular states) (fig. 2a). The epigenetic signatures of these 1,149 
genes were then evaluated for changes induced by 3D spheroid 
culture conditions. Interestingly, we found that among these com-
mon genes, a large number underwent epigenetic reprogramming 
through gain or loss of epigenetic marks. While a majority of 
monovalently marked genes in 2D cells transitioned to alternative 
monovalent, repressive marks in 3D (fig. 3a and sup. table s2), 
many other 2D-actively marked genes reshaped their pro-
moter regions to possess various alternative mono- or multiva-
lent histone marks in 3D (fig. 3a and 3B and sup. table s2). 
Significantly, 52% of the 2D genes possessing the H3Ac per-
missive mark retained an active mark in 3D culture, either as 
monovalent H3Ac (18%), H3K4me2 (19%) or both (H3Ac/
H3K4me2, 15%) (sup. table s2), suggesting that these genes 
remain active upon the change in micro-environment. Overall, 
however, the total number of active marks decreased in 3D 
H3K4me3/H3K9me3 and an interesting tetravalent combina-
tion, H3Ac/H3K4me2/H3K9me3/H3K27me3 (fig. 2B).
epigenetic flexibility contributes to ovarian cancer cell adap-
tation to a change in microenvironment (anchorage-dependent 
to -independent culture). We next investigated the epigenetic 
consequences of the altered cellular architecture and behavior 
induced by 3D cell culture. While similar numbers of monovalent 
marks were found in 2D and 3D cells (1879 vs. 1895), the com-
binations of H3 modifications among these genes were quite 
varied. While H3Ac was the most common overall (42% in 2D 
cells and 24% in 3D cells), H3K9me3 was more abundant in 
3D cells, equal to H3Ac at 24% (fig. 2c). Although H3K4me2 
was relatively similar between 2D and 3D cells (12 vs. 16%), 
a larger number of permissive marks (H3Ac and H3K4me2) 
were found in 2D culture, while 3D cells had more repressive 
histone marks overall (H3K9me3, 24 vs. 7% and H3K27me3, 
12 vs. 7%, 3D vs. 2D, respectively, fig. 2c). The H3Ac 
Figure 2. histone marks and their various combinations, are redistributed or erased upon 
transition from 2D to 3D culture. peakspicking detection of monovalent, bivalent, trivalent 
and tetravalent h3 modifications in 2D and 3D cells. (a) Monovalent marks. all genes (the 
top 10%, as determined by the peakspicking algorithm) were analyzed for the presence of 
individual histone marks. The proportion and type of such monovalently marked genes 
in 2D cells were compared to those in 3D cells. (B) Multivalent marks. all genes found by 
peakspicking were analyzed for the presence of multivalent histone marks. The proportion 
and type of such multivalent genes in 2D cells were compared to those in 3D cells.  
(c) Distinctiveness and overlap of histone-marked genes between the 2D and 3D cellular 
states. Of the 2,734 genes detected by peakspicking (top 10%) from 2D cells and 2,424 genes 
detected in 3D cells, 1149 were found to possess any of the four histone marks between the 
2D and 3D.
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H3K9me3/H3K27me3 (10 vs. 0.3%, fig. 2B) and the above-
mentioned tetravalent mark (2 vs. 0.1%, fig. 2B). Similar to the 
H3K27me3 monovalently marked genes (fig. 3a and bottom 
pie chart), bi- and tri-valent domains containing H3K27me3 
were also more likely to retain repressive marks, suggesting con-
tinued epigenetic repression by (the more stable) H3K27me3 
(sup. table s2). Tetravalent domains were much more common 
in 2D (55 genes) than in 3D (3 genes) cells (data not shown). 
However, while tetravalency was greatly decreased upon 3D cul-
turing, a substantial fraction (45%) of 2D-tetravalently marked 
genes remained bi- or trivalent (fig. 3B, top bar, sup. table s2).
epigenetic remodeling correlates with transcriptional 
changes and pathway dysregulation, following the 2d-to-3d 
transition. Overall, the presence of the little-known bivalent 
H3H3K4me2/H3K9me3 and tetravalent H3Ac/H3K4me2/
H3K9me3/H3K27me3 marks in ovarian cancer cells suggested 
possible epigenetic and phenotypic plasticity of the 2D cultures. 
Consequently, we performed transcriptome analysis of 2D- and 
3D-cultured CP70 cells, to examine possible correlations of 
gene expression with changes in histone marks (as assessed by 
our PeaksPicking analysis of the ChIP-chip results). Affymetrix 
gene expression arrays for CP70 2D and 3D cells were compared 
to normal ovarian surface epithelial cells (nOSE). As shown 
in figure 4a and B, 2D cell genes possessing the activating 
marks H3Ac and H3K4me2 were transcriptionally upregulated, 
(fig. 2c). Similarly, several genes possessing permissive 
H3K4me2 in 2D remained permissive in 3D culture, by either 
retaining H3K4me2 or changing H3K4me2 to H3Ac (12 and 
32%) and numerous 2D H3K9me3-repressed genes reverted to 
active chromatin by replacing H3K9me3 with H3Ac (49%, sup. 
table s2). The other repressive mark, H3K27me3, remained 
unchanged in 39% of genes (sup. table s2), thus representing 
the mark least likely to convert to an active H3Ac mark, sug-
gesting that its increased stability may serve an important role in 
maintaining gene repression.
Because 2D monolayer-cultured cells possessed a greater pro-
portion of multivalently marked genes than 3D cells (fig. 2B), 
we examined the fate of these potentially “plastic” genes upon 
3D culturing. This multivalency was generally lost upon CP70 
cell transition from 2D to 3D culture (855 genes in 2D vs. 275 
in 3D, a 68% decrease, data not shown), with 50% of the multi-
valent promoters becoming monovalent, primarily due to loss of 
the active H3 marks and retention of the repressive H3K27me3 
modification (fig. 3B). This resolution to monovalency suggests 
an overall loss of chromatin plasticity in 3D culture, due to the 
change in cellular architecture, with 3D conditions directing 
epigenetic fate toward more strict gene expression or repression. 
The multivalent domains that changed most significantly from 
2D to 3D included the well-studied bivalent mark H3K4me2/
H3K27me3 (6 vs. 1%, fig. 2B), the trivalent mark, H3K4me2/
Figure 3. Multivalently histone-marked promoters, abundant in 2D cells, resolve largely to repressive monovalency under 3D culture conditions. 
(a) Both active and repressive monovalent promoters in 2D cells become mostly monovalent and repressive in 3D cells. all genes containing a 
monovalent mark in 2D cells were analyzed for the presence of histone marks in 3D cells. Inner pie is modifications less than 5% abundance.  
(B) Multivalent marks in 2D cells become predominantly monovalent in 3D cells. 2D cells contained 31% multivalent marks, which decreased to 21% 
multivalent marks in 3D cells. The 2D gene possessing the ac + K4 + K9 mark was not marked in 3D cells. Black lines delineate monovalent marks from 
multivalent marks. all possible histone mark combinations are represented.
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(H3K9me3 and H3K27me3) marks in bivalent domains 
(fig. 4a, left part). By contrast, in 3D cells, the H3K4me2/
H3K9me3 and H3K4me2/H3K27me3 bivalent domains 
associated with transcriptional upregulation (fig. 4a, 
right part), suggesting a reversal of the dominant mark upon 
cellular transition to substrate independence, possibly to facil-
itate transcriptional activity allowing adaptation to this spe-
cific (3D) microenvironment.
To identify specific gene families or biological pathways, 
regulated by the aforementioned epigenetic patterns, the 
gene expression microarray datasets were subjected to Gene 
Set Enrichment Analysis (GSEA, www.broad.mit.edu/gsea). 
Hierarchical clustering demonstrated distinct segregation of 
the 2D and 3D gene expression patterns, (the 15 most upregu-
lated and 15 most downregulated genes between CP70 2D 
and 3D cells, fig. 4B and d). Members of the inhibitor of 
DNA binding (Id) family of genes (Id1, Id2, Id3) were most 
significantly downregulated in 3D cells, while matrix metal-
loprotease MMP genes were also downregulated (fig. 4B). 
Gene Ontology (GO, www.geneontology.org/) and GSEA 
determinations revealed that among the multivalently marked 
genes, genes for chromatin remodeling, development and cel-
lular differentiation were enriched (sup. table s3). Those 
results validated the ChIP-chip data, which showed numer-
ous up- or downregulated genes to associate, respectively, 
with the H3Ac/H3K4me2 activating (data not shown) or 
H3K9me3/H3K27me3 repressive (fig. 4a) marks. Opposing 
bivalently marked genes were not preferentially up- or down-
regulated, although the H3K27me3 mark generally associ-
ated with downregulation. Of the 20,700 annotated genes on 
the Affymetrix microarray, 5,514 (27%) showed significant 
fold-changes (p < 0.05). The significant expression changes in 
chromatin remodeling genes is supportive of a high degree of 
phenotypic plasticity.32
To further identify biological processes associated with 
altered histone marks in 3D culture, we analyzed four gene 
sets, with each having the permissive H3Ac mark in 2D and 
various histone marks in 3D, using the integrated database/
software suite MetaCore.33 This pathway analysis tool uses 
each gene in the set as a “node,” generating networks between 
the nodes, which are further broken down into smaller sub-
networks centered on receptors and transcription factors.33 
These four sets included: (A) 14 2D genes retaining the acti-
vating H3Ac mark in 3D; (B) eight genes with H3Ac replaced 
by the permissive H3K4me2 mark; (C) eight 2D genes 
having H3Ac replaced by the repressive mark H3K9me3 in 
3D and (D) 13 2D genes with H3Ac replaced by the binary 
permissive mark H3Ac/H3K4me2 in 3D. Other gene sets 
were excluded from the analysis due to: (1) their gene num-
ber was less than five; or (2) failure to infer significant sub-
networks. The results are shown in supplemental figure s2 
and table s4. For Group A genes, a 50-node network derived 
from the five nodes could be parsed into sub-networks involved 
in positive regulation of cell cycle and organelle organiza-
tion (sup. fig. s2a). Group B genes, however (4 nodes of a 
total of 50), formed a network negatively regulating cell cycle 
while those having the repressive histone marks H3K9me3, 
H3K27me3 and H3K9me3/H3K27me3 mark correlated with 
transcriptional downregulation, as predicted by the histone code 
hypothesis.3 Similarly in 2D cells, the bivalent marks H3K4me3/
H3K9me3 and H3K4me2/H3K27me3 associated with transcrip-
tional downregulation, suggesting dominance of the repressive 
Figure 4. “histone code”-based correlation of histone modification 
changes with changes in gene expression. (a) Box-plot analysis of gene 
expression and chromatin marks in 2D (left upper part) and 3D (right 
upper part) cp70 cells. Gene expression arrays were performed on 2D and 
3D cp70 cells and compared to those of nOsE cells, with changes in gene 
expression then correlated with specific chromatin marks associated with 
each gene. In accord with the histone code hypothesis, promoter-localized 
h3ac and h3K4me2 correlated with gene upregulation, while h3K9me3 
and h3K27me3 correlated with gene downregulation; genes having any 
two methylated h3 marks were mostly repressed. (B) DNa-binding, MMp 
and Wnt family genes are regulated by cellular architecture (2D vs. 3D). The 
most significant up-and-downregulated genes are shown.
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microRNA (miRNA)-mediated regulation of tumor suppressors 
and oncogenes, is strongly implicated in ovarian tumor progres-
sion,34-41 we evaluated a possible role for miRNA expression in 
microenvironment-associated epigenetic or genetic reprogram-
ming by custom microarray analyses42 of 2D and 3D CP70 cell 
cultures. Only minor miRNA changes were noted between the 
2D and 3D cultures, suggesting that miRNA profiles do not 
change significantly during this transition (fig. 5). However, the 
repressive H3K27me3 mark strongly associated with downregu-
lated gene expression (fig. 4a and both in 2D and 3D cells), 
and genes initially marked with H3K27me3 tended to retain 
the mark, thus reinforcing our earlier studies showing the stabil-
ity of this repressive modification (fig. 3 and sup. table s2). 
Consequently, we wished to examine the role of H3K27me3 in 
(sup. fig. s2B), while the network resulting from Group C genes 
(again 4 nodes of a total of 50) that positively regulated biologi-
cal processes including stress/stimulus responses and immune 
response (sup. fig. s2c and sup. table s4). Finally, the Group 
D (changing from H3Ac to H3Ac/H3K4me2) network included 
positive regulation of apoptosis (sup. table s4 and sup. fig. 
s2d). While reconciling these pathway predictions with our 
2D/3D culture is difficult, without further experimental valida-
tion (e.g., pathway reporters, pharmacologic inhibitors, etc.,), the 
analyses are consistent with the phenotypes of our 3D spheroids, 
including increased differentiation, decreased epigenetic plastic-
ity and slower proliferation (see above and previous section).
h3K27 trimethylation regulates microrna expression in 
cp70 cells. As another cancer-associated epigenetic phenomenon, 
Figure 5. miRNas are targeted during 2D to 3D transition. (a) miRNa microarray heat map. Top 15 upregulated and downregulated miRNa genes in 
cp70-K27R cells, as compared to the parental cp70 cells. a custom microarray84 was used to determine miRNa expression, using two replicates for 
each cell line. clustering of miRNa expression data was performed using cLUsTER,85 with filtering to remove inconsistencies between replicates. For 
clustering, we first log-transformed the data and median-centered the array and genes, followed by average linkage clustering. The expanded images 
flanking the heat map highlight the most significantly changed genes (p > 0.02, top 98%). No significant difference between replicated samples or 
between 2D and 3D for each cell line (p > 0.95).
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attributes of tumor progenitors,51 we isolated ovarian cancer-initi-
ating cells (OCICs) from human tumors,52 and compared OCIC 
histone patterns to CP70-H3K27R, bulk tumor cells, CP70-3D 
and CP70-2D cells (sup. fig. s4). In contrast to CP70-2D cells 
(but similar to CP70-3D cells), OCICs, CP70-H3K27R and 
bulk tumor cells possessed substantially fewer H3Ac-marked 
genes, with similar levels of the other monovalent and multiva-
lent marks (sup. fig. s4).
In another study of in vivo microenviromental effects on ovar-
ian cancer cells, we compared OCIC and bulk tumor cell ChIP-
chip results to those of an ascites-derived ovarian tumor-initiating 
clonal cell population,51 designated “A4.” Both OCICs and A4 
cells represent tumor progenitors capable of serially recapitulat-
ing their original ovarian tumors in nude mice.51,52 H3K27me3 
ChIP-chip assays of A4 cells identified 730 genes possessing this 
repressive mark, including inhibitor of DNA-binding (Id) fam-
ily of genes (GSEA analysis, data not shown) and the Polycomb 
(PcG) and Trithorax (TTX) gene families, chromatin-mod-
ifiers, developmental regulators (sup. table s5 and fig. 6). 
Furthermore, target genes of specific histone modifications were 
differentially expressed in tumors vs. spheroids formed in animal 
ascites, again suggestive of the influence of the in vivo micro-
environment. Specifically, A4-derived tumors overexpressed the 
PcG genes EED and L3MBTL and the DNA methyltransferase 
gene DNMT3B, with downregulation of the histone H3K9me3 
demethylase (thus gene-activating) gene JMJD1A, as compared 
to expression levels in steady state, monolayer A4 cells (fig. 6). 
In A4-derived spheroids, however, expression of JMJD1A and the 
PcG gene L3MBTL was decreased, while the PcG gene SUZ12 
was increased >6-fold (fig. 6). The variable expression of chro-
matin-remodeling genes, with diverse combinations of histone 
marks, is highly suggestive of phenotypic plasticity, similar to 
differentiation of embryonic stem cells.32
repression of miRNA expression, utilizing a previously established 
CP70 cell subline (CP70-H3K27R) expressing a dominant-nega-
tive histone H3 having lysine 27 replaced by (the similarly basic 
residue) arginine.43
Western blot analysis of CP70-H3K27R cells revealed, as we 
demonstrated previously,43 a decrease of the H3K27me3 mark, in 
addition to an increase of the activating H3Ac mark, as compared 
to the parental CP70 cell line cultured under 2D or 3D condi-
tions (sup. fig. s3). Further comparison of CP70-H3K27R cells 
under both 2D- and 3D-culture conditions revealed a dramatic 
difference in miRNA profiles (fig. 5, left and right insets). Loss 
of H3K27me3 methylation resulted in distinct up- or downregu-
lated miRNA gene families, demonstrating a strong role for this 
mark in regulating miRNA expression. The largest cluster of sig-
nificantly overexpressed miRNA genes in CP70-H3K27R cells 
was the miR-200 family (fig. 5, right inset), well known suppres-
sors of the metastasis-associated epithelial-to-mesenchymal tran-
sition.44-47 These results also suggest that the repressive histone 
mark H3K27me3 may play a role in ovarian cancer metastasis, 
as the H3K27-trimethylating enzyme, EZH2, is overexpressed 
in highly aggressive (and metastatic) breast and prostate can-
cers.48-50 Thus, both miRNA-mediated epigenetic regulation, 
as well as the reciprocal epigenetic-induced changes in miRNA 
expression, highlights an additional complexity in ovarian cancer 
epigenomics.
ovarian tumor, xenografts and ovarian cancer stem cells 
extensively possess the h3K27me3 repressive mark. To further 
investigate the in vivo occurrence of the four H3 marks, and their 
possible roles in tumor initiation and progression, we performed 
ChIP-chip analyses on DNA from ovarian cancer stem-like 
cells and bulk tumor cells. Based on the increasingly accepted 
“cancer stem cell hypothesis,” a distinct tumor subpopulation of 
malignant progenitors is directly responsible for tumor growth, 
drug resistance and metastasis.18,19 Based on recently described 
Figure 6. Flexibility of gene expression in xenografts. RT-qpcR results indicating flexibility of gene expression of monolayer cp70 cultured cells vs. a 
primary sub-cutaneous tumor (a4 s.c) vs. spheroids in peritoneal metastases (a4 sph-vivo). Q-pcR standard curves were produced in triplicate and ct 
values used to determine relative expression analysis. The measured ct value was further used to estimate the transcripts levels. Beta-actin was used 
as a reference housekeeping gene, with expression levels normalized to those of the same genes as expressed in normal ovarian surface epithelial 
(nOsE) cells.
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cells may be epigenetically “reprogrammed” to a stem-like chro-
matin state.16,17 Specifically, this “induced pluripotency” occurs 
in the absence of changes in DNA sequence, and is associated 
with widespread remodeling of chromatin;16,56 interestingly, one 
agent that greatly facilitated induced pluripotency was the his-
tone deacetylase inhibitor valproic acid.57 A somewhat analogous 
phenomenon, “transdifferentiation,” is the process whereby a 
terminally differentiated cell transposes to a disparate lineage;17 
examples of transdifferentiation include the conversion of mam-
mary adipocytes into secretory epithelial cells during pregnancy 
and lactation (with the subsequent reversion to adipocytic tissue 
following weaning) and the development-associated, recriprocal 
conversion between hepatocytes and pancreatic exocrine cells.58,59 
Similarly, we also observed differentiation-altering, microen-
vironment-associated plasticity in CP70 cells, demonstrating 
reduced epigenetic plasticity upon their transition from 2D to 
3D culture. Those results also showed H3K27me3 as a stable 
repressive mark, in accord with prior studies demonstrating (the 
H3K27me3-associated) Polycomb proteins to mediate repression 
in stem/cancer cells and to “pre-mark” specific genes for subse-
quent DNA methylation.8,12,14,31,60 Additionally, CP70-H3K27R 
cells (largely incapable of H3K27 trimethylation)43 demonstrated 
significantly altered miRNA expression patterns (fig. 5).
Similar to differentiated somatic cells, cancer cells can also 
retain considerable epigenetic plasticity that is influenced by exter-
nal cues. The increasingly accepted “cancer stem cell” hypothesis 
regards a tumor as an abnormal organ, possessing a hierarchy 
of progeny cells derived from multipotent tumor progenitors;18,19 
our group identified such progenitors in human ovarian cancer 
patients’ ascites51 and primary tumors.52 Because advanced-stage 
carcinoma cells exhibit considerable phenotypic plasticity (allow-
ing for adaptation to diverse microenvironments), this plastic-
ity could possibly be exploited against those cells to circumvent 
their malignant potential. For example, melanoma cells, when 
plated atop ESC-derived extracellular matrices, remarkably, dif-
ferentiate into sphere-forming melanocytes, while undifferenti-
ated melanoma cells grow only as monolayers.22,23 Analogously, 
the melanocyte-containing spheres can be “de-differentiated” 
into two-dimensional melanoma cells when plated atop mela-
noma cell-derived extracellular matrices.23 Epigenetic plasticity 
has also been shown by similar reversion of aggressive breast can-
cer cells,22 and indeed, many inhibitors of epigenetic repressive 
enzymes (e.g., DNA methyltransferase and histone deacetylase 
inhibitors) are well established differentiating agents.4,61 Thus, 
even advanced-stage cancer cells, despite considerable genetic 
damage, retain considerable epigenetic plasticity in response to 
their specific microenvironments, which can either facilitate or 
hinder malignant progression.
In extension to prior studies of ESC, melanoma, and breast 
cancer cells, we now demonstrate epigenetic plasticity in mono-
layers of ovarian cancer cells, with frequent promoter co-localiza-
tion of transcriptionally opposing bi-, tri- and tetra-valent histone 
marks. This epigenetic plasticity, permissive for transcriptional 
changes, might reflect the inherent phenotypic flexibility of the 
normal ovarian surface epithelium (nOSE), whose mesenchymal 
properties facilitate postovulatory wound repair.62 Such flexibility 
Similarly, several H3K9me3-associated genes (13%) were also 
found dysregulated in spheroids. However, genes associated with 
the H3K9me3 mark alone (6%) exhibited only limited transcrip-
tional flexibility, while tetravalency correlated with highly plastic 
gene expression (38%, data not shown). These profiling stud-
ies demonstrate the complex influence of expression patterns of 
key cancer cell genes on higher order chromatin remodeling, in 
response to cell-extrinsic signals emanating from in vitro vs. in 
vivo microenvironments.
Discussion
The phenomenon known as “epigenetic plasticity,” (i.e., a flex-
ibility of chromatin modifications) is a phenotype of uncommit-
ted cells that is progressively lost during lineage commitment, 
due largely to cues from the local stroma, extracellular matrix, 
autocrine/paracrine loops and ligand/receptor interactions on 
juxtaposed cells.53 In tissue and embryonic stem cells (ESCs), 
epigenetic plasticity is associated with “bivalent” gene promot-
ers concurrently possessing a transcriptionally repressive his-
tone mark, trimethylated histone H3 lysine 27 (H3K27me3) 
and a permissive mark, di-/tri-methylated histone H3 lysine 4 
(H3K4me2/3).6,7,42 Moreover, several ESC-bivalently marked 
genes are also DNA-methylated in colon tumors,26 supporting 
the long-held analogy of cancer as a reversion to an embryonic-
like state.54 Consequently, to assess epigenetic plasticity in ovar-
ian cancer, we utilized the cisplatin-resistant, aggressive cell line 
CP70 to globally examine (using “ChIP-chip” analyses) four 
well-known histone marks, the activating marks, H3K4me2 
and acetylated histone H3 (H3Ac) and the repressive marks, 
H3K27me3 and trimethylated histone H3 lysine 9 (H3K9me3). 
The vast majority of these marks localized to gene promoters 
and first exons (fig. 1c), while also conforming to the “histone 
code” hypothesis,3 with activating marks correlating with gene 
upregulation and repressive marks correlating with gene down-
regulation (fig. 4a). We next examined the effect of the local 
microenvironment on CP70 epigenetic plasticity in response 
to two cellular conditions commonly present in ovarian malig-
nancies, three-dimensional multicellular aggregates (spheroids) 
and two-dimensional monolayers, typically present in patients’ 
ascites and peritoneal mesothelia, respectively.28,55 Those two 
disparate microenvironments correlated with numerous altered 
histone modifications and gene expression levels (fig. 4 and 
sup. table s3), predicting significant dysregulation of various 
biological processes (sup. fig. s2 and sup. table s4). Moreover, 
our ChIP-chip assessments identified several previously unchar-
acterized multivalent histone marks, facilitating a “transcription-
ready” chromatin state of various proto-oncogenes and stemness 
and chromatin-remodeling genes (sup. fig. s5). These assess-
ments also highlight a functional role for the bivalent H3K4me2/
H3K9me3 mark, for the first time, in aggressive cancer cells, in 
addition to the largely unknown binary H3K9me3/H3K27me3, 
trivalent H3K4me2/H3K9me3/H3K27me3 and tetravalent 
H3Ac/H3K4me2/H3K9me3/H3K27me3 marks.
While epigenetic plasticity is well associated with normal 
stem cell lineage commitment, even terminally differentiated 
www.landesbioscience.com Epigenetics 725
Materials and Methods
cell culture, cell lines and tumor samples. Cisplatin-resistant 
CP70 ovarian cancer cells (a kind gift from Dr. Robert Brown, 
Imperial College London and Institute of Cancer Research, UK) 
were used to generate the primary chromatin immunoprecipita-
tion DNA microarray hybridization (ChIP-chip) data. To cor-
relate the epigenetic marks associated with genes differentially 
expressed in the various ovarian cancer and ovarian cancer-
derived cell types, we subjected the CP70 cells to 2D or 3D cul-
ture conditions. To generate 3D cultures, CP70 cells were grown 
in a liquid basal medium (RPMI without any serum) in low-
adherence dishes at 37oC for 3–4 days and were harvested by 
centrifugation.
All cell lines used are listed in supplemental table s1. A4 
is a cell line previously established from a single isolated cell 
derived from a multi-layered spheroid present in the ascites of 
a serous ovarian epithelial cancer patient,51 and was maintained 
in MEM(E), 5% FBS and 1% nonessential amino acids (each 
from Gibco Invitrogen, Carlsbad, CA, USA). Furthermore, we 
examined the epigenetic status of ovarian cancer stem-like cells 
(CSCs),51 ovarian cancer-initiating cells (OCICs),52 and ovar-
ian side-population (SP) cells,75 for the presence of multiva-
lantly marked gene promoters. Human ovarian tissue and tumor 
samples were obtained by informed consent, and all studies were 
approved by the Institutional Review Boards of the National 
Centre for Cell Science, Indiana University and the Ohio State 
University. Normal ovarian surface epithelial (nOSE) cells were 
acquired from patients during surgery for benign gynecological 
disease, as previously described,76 with cytokeratin and vimentin 
staining to validate their dual epithelial/mesenchymal character.62
chromatin immunoprecipitation and dna microarray 
analysis (chip-chip). All antibodies used for ChIP were from 
Millipore (Billerica, MA, USA): acetylated histone H3 (cata-
log #06-599), H3K4me2 (#07-030), H3K9me3 (#07-441) and 
H3K27me3 (#07-449) and chromatin immunoprecipitation 
to microarray hybridization carried out as we described previ-
ously.77 Independent immunoprecipitations were performed for 
each analysis. Approximately 108 cells CP70 cells were used for 
each experiment. Cells were chemically crosslinked by the addi-
tion of one-tenth volume of fresh 11% formaldehyde solution for 
15 min at room temperature, rinsed twice with ice-cold 1X 
PBS and harvested using a silicon scraper. The harvested cells 
were then resuspended in lysis buffer and sonicated to solubilize 
and shear crosslinked DNA to a size range of ~500–1,000 bp. 
Samples were kept on ice at all times. The resulting whole cell 
extract was incubated overnight at 4°C with 80 ml Protein 
A-agarose magnetic beads that had been pre-incubated with 
approximately 10 mg of the appropriate antibody. Bound com-
plexes were further eluted from the beads in TE buffer after 
sequential washing with low salt, high salt and LiCl buffers and 
crosslinks then removed by adding NaCl to the eluted DNA 
and heating overnight at 65°C. Whole cell extract DNA (non-
immunoprecipitated, reserved from the sonication step as a 
positive control) was also treated for crosslink reversal and the 
ChIPed and whole cell extract DNA then treated with RNaseA 
was lost or restructured in the 3D state, which had less multiva-
lency and more repressive monovalent marks (concomitant with 
a loss of permissive marks, fig. 3B and sup. table s2). While 
other in vitro cultured multiaggregate spheroids were enriched 
in stem cells (i.e., less differentiated), this property would appear 
to be tissue-specific (including neural and mammary tissues),63,64 
as other sphere-forming cells actually demonstrate reduced dif-
ferentiation capacity (i.e., reduced plasticity/stemness).65,66 It 
is conceivable that our in vitro spheroids resemble those in the 
abovementioned melanoma differentiation studies. However, 
our in vivo ascites-derived spheroids also overexpressed vari-
ous Polycomb proteins (fig. 6), which facilitate tumor cell self-
renewal and associate with poor differentiation and metastatic 
phenotypes,49,50,67 consistent with the in vivo properties of these 
ovarian tumor-derived structures.28,55
While the cell-of-origin of epithelial ovarian cancer remains 
unclear, it appears that (in contrast to other carcinomas) early 
stage disease is characterized by a “mesenchymal-to-epithelial 
transition.” 62,68,69 During malignancy progression, tumor-exfoli-
ated spheroids (possibly analogous to our currently used culture 
system) transcoelomically migrate or traverse through ascites 
fluid (while also avoiding immunodetection), followed by attach-
ment to the collagen-rich peritoneal mesothelial monolayer, 
forming multiple, invasive foci (a process known as “peritoneal 
seeding”).28,55 Those mesothelium-attached cells must exhibit 
a large degree of phenotypic adaptability, including integrin- 
and cadherin-associated submesothelial anchoring, secondary 
tumor outgrowth, invasiveness and the establishment of matrix-
rich, channel-forming networks expressing vascular markers 
(“vasculogenic mimicry”).28,70,71 These late-stage events show a 
high degree of adaptability unlikely to be mediated by genetic 
mutation alone,72 and in contrast to early stage malignancy, 
these advanced disease phenotypes associate with typical EMT,68 
largely regulated by epigenetic permutations.39,62,69 Moreover, 
another study demonstrated tumorigenic capacity of ascites-
derived ovarian cancer cells to be highly dependent on their 
local microenvironmental “niche.”73 Thus, the increased epigen-
etic plasticity of monolayered (vs. sphere-forming) ovarian can-
cer cells might facilitate the necessary phenotypic diversity that 
allows for adaptation to the harsh conditions encountered during 
ovarian cancer metastasis. Although we did not examine rever-
sion of the 3D state to the 2D state, those previously well estab-
lished in vivo findings, in combination with our current study, 
would allow us to predict a re-establishment of epigenetic and 
phenotypic plasticity under monolayer conditions.
In summary, our integrated genomic, epigenomic and 
miRNA assessment reveals a complex network of epigenetic-
mediated regulation of gene and miRNA expression which is 
largely influenced by the cellular microenvironment.74 Similar to 
previous studies of breast cancer and melanoma, our findings of 
multivalent histone marks extend the attribute of epigenetic plas-
ticity to ovarian cancer. As this plasticity is strongly influenced 
by the cancer cell microenvironment, characterization of the sig-
nal cascades responsible for relaying external cues to the nuclear 
epigenetic machinery could provide new strategies for combating 
this devastating malignancy.
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Hercules, CA, USA), using 20 ml reactions containing buffer, 
1.5 mM MgCl
2
, 0.2 mM dNTPs, 10 pM of each primer and 
0.2 units of recombinant Taq DNA polymerase, as we have pre-
viously described.43,78 Amplifications were performed in trip-
licate. Q-PCR standard curves were produced in triplicate and 
Opticon Monitor software was used to calculate C
t
 (threshold 
cycle) relative gene expression values, using the well established 
2exp(-DDC
t
) method,79 with normalization to expression levels 
of the same genes in primary cultured nOSE cells. In addition to 
SYBR green fluorescent detection, the amplified products were 
also resolved on 1.8% agarose gels and visualized by staining 
with ethidium bromide. Densitometric analysis was done using 
Genetools 3.6 (Syngene, Cambridge, England). Gene expression 
levels were normalized to the expression of the housekeeping gene 
b-actin.
statistical analysis. Affymetrix (Santa Clara, CA, USA) 
Human Genome U133 Plus 2.0 Arrays, consisting of 54,614 
probe sets, were used for measuring basal level gene expression 
in CP70 cells. Three biological and three control samples were 
assessed, with the resulting Affymetrix image files (*.CEL files) 
analyzed simultaneously and normalized using the RMA algo-
rithm provided in the Affymetrix Expression Console software, 
as we have described previously.78 Probe sets were annotated 
using RefSeq and full-length GenBank Transcripts (ncbi.nlm.
nih.gov), resulting in 20,554 annotated genes. A log
2
 scale was 
used for calculating the intensity of each Affymetrix gene probe 
for each sample and Welch’s test used to compute p values (with 
p < 0.05 used as a cutoff threshold). Box plots were performed 
using R2.9.2 (www.r-project.org/).
cluster analysis, gene set enrichment analysis (Gsea) and 
network/sub-network predictions. Hierarchical clustering and 
GSEA analyses were performed as we have described previ-
ously.80,81 Briefly, clustering of the miRNA and mRNA microar-
ray profiles was performed using Cluster 3.0 (J. van Huissteden, 
Vrije Universiteit, Amsterdam, The Netherlands, www.falw.
vu/~huik/cluster.htm). The profiles were first pre-filtered by 
the fraction present and then input into the program, in which 
they were further log-transformed. Expression values were nor-
malized by array median centering and gene median centering 
and average linkage clustering was performed by using a correla-
tion (centered) similarity metric. Clustering results were viewed 
using TreeView version 1.60 (Michael Eisen, Stanford University, 
rana.lbl.gov/EisenSoftware.htm). GSEA is a method for evaluat-
ing specific gene sets based on prior knowledge, about biochemi-
cal pathways or coexpression in previous experiments. GSEA 
determines whether the specific genes in a set tend to occur ran-
domly or toward the top (or bottom) of a sorted gene list, based 
on correlation of the gene set calculated by an enrichment score 
at particular significance level.82 Specific biological pathways 
were defined by the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) database (Kanehisa Laboratories, Japan, www.genome.
jp/kegg/).
For additional pathway analysis, gene datasets, corresponding 
to various 2D-to-3D histone mark alterations and gene expres-
sion changes, were analyzed using a trial version of the integrated 
software suite MetaCore™ (GeneGo, St. Joseph, MI, USA 
and proteinase K, followed by purification using DNeasy col-
umns (QIAGEN, Valencia, CA, USA). The purified DNA was 
then blunted, ligated to linkers and amplified using a two-stage 
PCR protocol. Amplified DNA was labeled using Bioprime ran-
dom primer labeling kits (Invitrogen). ChIP’ed DNA was labeled 
with Cy5 fluorophore, while whole cell extract DNA was labeled 
with Cy3. Cy3- and Cy5-labeled DNA (5 mg of each) was mixed 
and hybridized to 244 K Agilent G4492A Human CpG island 
microarrays (Santa Clara, CA, USA), using Agilent hybridization 
chambers for 40 hours at 40°C. After hybridization, arrays were 
washed and scanned, using an Axon GenePix® 4,200. A scan-
ner and GenePix® (version 6.0) software (Molecular Devices, 
Sunnyvale, CA, USA) used to automatically align the data, 
while abnormal features were identified manually, resulting in 
the final hybridization intensity results. The binding regions on 
each promoter were identified using the peaksPicking program 
developed in our previous study.30 Briefly, this program employs 
a probe-based enrichment threshold to define peaks (binding 
regions) for each promoter array, determining three enrichment 
threshold levels (top 1%, top 5% and top 10%), followed by a 
permutation-based statistical method to control the false discov-
ery rate for peaks identified at each enrichment threshold.30 The 
identified binding regions are then mapped to the UCSC HG17 
RefGene human genome database to locate the corresponding 
target genes.30 In the current study, the percentage of number 
of genes was based on the total 16,264 annotated genes on the 
Agilent G4492A array. Histone mark localizations were deter-
mined using the UCSC HG17 RefGene reference database, with 
gene promoter regions defined as -2 kb to +2 kb of the TSS of any 
specific gene.
rna preparation, microarray hybridization, data analysis 
and validation. Total RNA was prepared using the QIAGEN 
RNeasy MiNi Kit. A DNase I digestion step was included to 
eliminate DNA contamination. cRNA was generated, labeled 
and hybridized to the Affymetrix Human Genome U133 Plus 
2.0 Arrays by the Center for Medical Genomics at Indiana 
University School of Medicine (http://cmg.iupui.edu/), as we 
have described previously.78 The hybridized Human Genome 
U133A 2.0 Array was scanned and analyzed using the Affymetrix 
Microarray Analysis Suite (MAS) version 5.0. The average den-
sity of hybridization signals from four independent samples was 
used for data analysis and genes with signal density less than 300 
pixels were omitted from the data analysis.
rna isolation, reverse-transcription pcr (rt-pcr) and 
real-time quantitative pcr (q-pcr). Total RNA was extracted 
from cultured cells, tumors or ascites using TRIzol reagent 
(Invitrogen). The primary tissue samples were initially harvested 
and placed in liquid nitrogen before lysis and homogenization 
in TRIzol, whenever necessary. The concentration and purity of 
RNA was measured by A
260
/A
280
 measurements using a Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA). For quantitative PCR (qPCR) analysis, 2 mg total RNA 
was reverse transcribed using random hexamer primers and the 
SuperScript® First-Strand Synthesis System (Invitrogen) to pro-
duce cDNA, which was then used as the qPCR template, per-
formed in a Mini Opticon real-time thermal cycler (Bio-Rad, 
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little-characterized multivalent histone marks, including a pos-
sible in vitro and in vivo functional role for the largely unknown 
bivalent mark, H3K4me2/H3K9me3. Additionally, we have 
now identified bivalent H3K4me2/H3K9me3 and H3K9me3/
H3K27me3, trivalent H3K4me2/H3K9me3/H3K27me3 and 
tetravalent H3Ac/H3K4me2/-H3K9me3/H3K27me3 domains 
in cancer cells, further illustrating the influence of higher order 
chromatin regulation on phenotype adaptability. Upon a com-
monplace alteration in cellular microenvironment, transition 
from anchorage dependence to anchorage independence, we uti-
lized an integrative approach to associate phenotype with chro-
matin remodeling and transcriptome alterations, suggesting that 
the necessary phenotypic adaptations are mediated by epigenetic 
responses to reorganization of cellular architecture. A greater 
understanding of the mechanism(s) responsible for these micro-
environment-influenced chromatin alterations will likely lead to 
improved epigenetic strategies to reduce tumor cell adaptation 
and possibly, even diminish or revert the malignant characteris-
tics of these cells.
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www.genego.com).33 This pathway analysis tool employs a vast, 
manually curated database of interactions between biological 
objects and a variety of tools for functionally analyzing high-
throughput data. Networks and sub-networks enriched for the 
input genes are generated by a database and depicted by the 
MapEditorTM module of the software suite. Sub-networks are 
determined using a p value based on overrepresented pathways. 
Only significant (p < 0.05) maps were considered and subjected 
to Gene Ontology (www.geneontology.org) terms and pro-
cesses. For a key to the various symbols and interactions between 
objects, please visit the MetaCoreTM Quick Reference legend at 
www.genego.com/pdf/MC_legend.pdf.
microarray analysis of mirna in cp70 cells. A custom 
microarray33 was used to determine miRNA expression, using 
two replicates for each cell line, as we have described previ-
ously.83 Clustering of miRNA expression data was performed 
using CLUSTER,85 with filtering to remove inconsistencies 
between replicates. For clustering, we first log-transformed 
the data and median-centered the array and genes, followed 
by average linkage clustering. Clustering results were visual-
ized by TreeView (http://rana.lbl.gov/EisenSoftware.htm). The 
expanded images flanking the heat map highlight the most sig-
nificantly changed genes (p > 0.02, top 98%). The top 98% 
of significantly changed miRNA included 16 downregulated 
miRNAs in K27R cells and 24 upregulated miRNAs in K27R 
cells compared to CP70. No significant differences were found 
between replicated samples or between 2D and 3D for each cell 
line (p > 0.95) graphs in “miRNA microarray raw data + fold-
change.xls”).
Conclusions
Epigenetic plasticity is well known to facilitate phenotypic adap-
tation, in response to external signals, during normal mam-
malian development, and also likely promotes the abnormal 
differentiation that occurs in tumor initiation and progression. 
Similarly, it has now been demonstrated that even advanced-
stage breast cancer and malignant melanoma cells possess 
considerable epigenetic plasticity that is responsive to external 
differentiation cues,22,23 while various inhibitors of epigenetic 
repression are well established differentiating agents.61 In the 
current study, we extend this attribute of microenvironment-
responsive epigenetic plasticity to ovarian cancer and can-
cer stem-like cells, as mediated by well-known and previously 
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